Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa
Frontiers in Cellular and Infection Microbiology · 2023
DOI: 10.3389/fcimb.2023.1023948 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Yixin Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Diseases, The first Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Sepsis, Pseudomonas Infections. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate the efficacy of ceftazidime-avibactam (CZA) and aztreonam-avibactam (AZA) against bloodstream infections (BSIs) or lower respiratory tract infections (LRTIs) – caused by extensive drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa.
Method
The two-fold dilution method was used to determine the minimum inhibitory concentrations (MICs) of CZA/AZA against XDR/PDR P. aeruginosa . Whole-genome sequencing was used to analyze the resistance determinants of each isolate. Monte Carlo simulations (MCSs) were used to evaluate the probability of target attainment (PTA) and the cumulative fraction of response (CFR) of each CZA/AZA dosing regimen via traditional infusion (TI)/optimized two-step-administration therapy (OTAT).
Results
We found that XDR/PDR P. aeruginosa may carry some rare MBLs (e.g.: IND-6, SLB-1, THIN-B). P. aeruginosa isolates producing IMP-45, VIM-1, or VIM-2 were inhibited by AZA at a concentration of 2 to 8 mg/L. All isolates producing IND-6 plus other serine β-lactamases were high-level resistant to CZA/AZA (MICs >64 mg/L). All simulated dosing regimens of CZA/AZA against BSIs-causing XDR/PDR P. aeruginosa achieved 100% PTA when the MIC was ≤32 mg/L.
Conclusion
AZA has been considered as an option for the treatment of infections caused by XDR/PDR P. aeruginosa producing IMP-45, VIM-1, or VIM-2. OTAT with sufficient pharmacodynamic exposure may be an optimal treatment option for XDR/PDR P. aeruginosa with a high-level MIC of CZA/AZA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Diseases, The first Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
- Medical School of Chinese People's Liberation Army (PLA), Beijing, China.
- Research Center for Micro-Ecological Agent Engineering and Technology of Guangdong Province, Guangzhou, China.
- Department of Laboratory, The First Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
- College of Pulmonary & Critical Care Medicine, 8th Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Zitieren
APA
Kang, Y., Xie, L., Yang, J., & Cui, J. (2023). Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1023948
Vancouver
Kang Y, Xie L, Yang J, Cui J. Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1023948
BibTeX
@article{Kang2023,
author = {Kang, Yixin and Xie, Lu and Yang, Jiyong and Cui, Junchang},
title = {Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
doi = {10.3389/fcimb.2023.1023948}
}
EUVIMED